Cited by 415Cancer Genomics and DiagnosticsLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

Punnoose, Elizabeth A., Atwal, Siminder, Liu, Weiqun, Raja, Rajiv, Fine, Bernard M., Hughes, Brett G.M., Hicks, Rodney J., Hampton, Garret M., Amler, Lukas C., Pirzkall, Andrea, Lackner, Mark R.·2012·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-11-3148

Published version of a preprint

Open this paper in CoChat — free account

Abstract

PURPOSE: Elevated levels or increases in circulating tumor cells (CTC) portend poor prognosis in patients with epithelial cancers. Less is known about CTCs as surrogate endpoints or their use for predictive biomarker evaluation. This study investigated the utility of CTC enumeration and characterization using the CellSearch platform, as well as mutation detection in circulating tumor DNA (ctDNA), in patients with advanced non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN: Forty-one patients were enrolled in a single-arm phase II clinical trial of erlotinib and pertuzumab. Peripheral blood was analyzed for CTC enumeration, EGFR expression in CTCs, and detection of oncogenic mutations in CTCs and ctDNA. Changes in CTC levels were correlated with 2[18F]fluoro-2-deoxy-D-glucose-positron emission tomographic (FDG-PET) and computed tomographic (CT) imaging and survival endpoints. RESULTS: CTCs were detected (≥ 1 CTC) at baseline in 78% of patients. Greater sensitivity for mutation detection was observed in ctDNA than in CTCs and detected mutations were strongly concordant with mutation status in matched tumor. Higher baseline CTC counts were associated with response to treatment by Response Evaluation Criteria in Solid Tumors (RECIST, P = 0.009) and decreased CTC counts upon treatment were associated with FDG-PET and RECIST response (P = 0.014 and P = 0.019) and longer progression-free survival (P = 0.050). CONCLUSION: These data provide evidence of a correlation between decreases in CTC counts and radiographic response by either FDG-PET or RECIST in patients with advanced NSCLC. These findings require prospective validation but suggest a potential role for using CTC decreases as an early indication of response to therapy and ctDNA for real-time assessment of mutation status from blood.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-11-3148

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,602
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Bono, J. S. D., Scher, H. I., Montgomery, B., Parker, C. C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. M. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,189
Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
Cohen, S. J., Punt, C. J. A., Iannotti, N. O., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E. P., Miller, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8923 · Cited by 1,876
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations
Young, H. E., Baum, R. P., Cremerius, U., Herholz, K., Hoekstra, O. S., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,716
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S., Herbst, R. S., Ince, W. L., Janne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,453
Self-citation

Show all 29 references

Research works printed but not linked: 2

Ries, 2005, Cancer Statistics Review, 1975–2002
Hughes B, 2011, Combination of pertuzumab and erlotinib as 2nd/3rd-line treatment for patients with metastatic non-small cell lung cancer: safety and anti-tumour activity by FDG-PET/CT imaging changes, ECCO/ESMO European Multidisciplinary Congress; 23–27

Sorted by citations

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Liquid biopsy: monitoring cancer-genetics in the blood
Crowley, E. H., Nicolantonio, F. D., Loupakis, F., & Bardelli, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.110 · Cited by 1,857
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624
Circulating tumor cells: biology and clinical significance
Lin, D., Shen, L., Luo, M., Zhang, K., Li, J., Yang, Q., Zhu, F., Zhou, D., Zheng, S. S., Chen, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00817-8 · Cited by 1,046
Liquid biopsy: current technology and clinical applications
Nikanjam, M., Kato, S., & Kurzrock, R. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01351-y · Cited by 963
Circulating Tumor DNA as a Liquid Biopsy for Cancer
Heitzer, E., Ulz, P., & Geigl, J. B. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.222679 · Cited by 783
Molecular analysis of circulating tumour cells—biology and biomarkers
Krebs, M., Metcalf, R. L., Carter, L., Brady, G., Blackhall, F. H., & Dive, C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.253 · Cited by 638
The emerging role of cell-free DNA as a molecular marker for cancer management
Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2019) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2019.100087 · Cited by 566
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
Thress, K. S., Brant, R., Carr, T. H., Dearden, S. P., Jenkins, S. C., Brown, H. J., Hammett, T., Cantarini, M., & Barrett, J. C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.004 · Cited by 494
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer
Aggarwal, C., Thompson, J. C., Black, T. A., Katz, S. I., Fan, R., Yee, S. S., Chien, A. L., Evans, T. L., Bauml, J. M., Alley, E. W., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4305 · Cited by 488
EMT, CTCs and CSCs in tumor relapse and drug-resistance
Mitra, A., Mishra, L., & Li, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4037 · Cited by 467
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
Tan, C., Gilligan, D., & Pacey, S. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00246-6 · Cited by 393
Lung Cancer Staging and Prognosis
Woodard, G. A., Jones, K. D., & Jablons, D. M. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40389-2_3 · Cited by 382
Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility
Ignatiadis, M., Lee, M., & Jeffrey, S. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1190 · Cited by 363
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Thompson, J. C., Yee, S. S., Troxel, A. B., Savitch, S. L., Fan, R., Balli, D., Lieberman, D. B., Morrissette, J. D., Evans, T. L., Bauml, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1231 · Cited by 325
“Moreover, ctDNA is readily detectable in the blood of a patient with lung cancer (20, 27, 29, 30), and sensitivity of variant detection was recently shown to be higher in ctDNA than CTCs (25).”
Background
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
Kerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T. S. K., Novello, S., O'Byrne, K. J., Stahel, R. A., Peters, S., Felip, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu145 · Cited by 306
Clinical applications of the CellSearch platform in cancer patients
Riethdorf, S., O′Flaherty, L., Hille, C., & Pantel, K. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.011 · Cited by 278
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer
Jenkins, S., Yang, J. C.-H., Ramalingam, S. S., Yu, K., Patel, S., Weston, S., Hodge, R., Cantarini, M., Jänne, P. A., Mitsudomi, T., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.003 · Cited by 269
The kinome 'at large' in cancer
Fleuren, E. D. G., Zhang, L., Wu, J., & Daly, R. J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2015.18 · Cited by 268
Circulating tumor cell isolation, culture, and downstream molecular analysis
Sharma, S., Zhuang, R., Long, M., Pavlović, M. D., Kang, Y., Ilyas, A., & Asghar, W. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.03.007 · Cited by 247
Targeted therapies for renal cell carcinoma
Posadas, E. M., Limvorasak, S., & Figlin, R. A. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.82 · Cited by 246
Size-based separation methods of circulating tumor cells
Hao, S.-J., Wan, Y., Xia, Y.-Q., Zou, X., & Zheng, S.-Y. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.002 · Cited by 242
Biomimetic Immuno‐Magnetosomes for High‐Performance Enrichment of Circulating Tumor Cells
Xiong, K., Wei, W., Jin, Y., Wang, S., Zhao, D., Wang, S., Gao, X., Qiao, C.-M., Yue, H., Ma, G., et al. (2016) · Advanced Materials · doi:10.1002/adma.201601643 · Cited by 230
Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?
Zhang, W., Xia, W., Lv, Z., Ni, C., Yin, X., & Yang, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000458736 · Cited by 236
Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities
Habli, Z. S., AlChamaa, W., Saab, R. H., Kadara, H. N., & Khraiche, M. L. (2020) · Cancers · doi:10.3390/cancers12071930 · Cited by 234
Platelet–Leukocyte Hybrid Membrane‐Coated Immunomagnetic Beads for Highly Efficient and Highly Specific Isolation of Circulating Tumor Cells
Rao, L., Meng, Q., Huang, Q., Wang, Z., Yu, G., Li, A., Ma, W., Zhang, N., Guo, S., Zhao, X., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201803531 · Cited by 226
Self-citation
Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
Zheng, D., Ye, X.-R., Zhang, M. Z., Sun, Y., Wang, J. Y., Ni, J., Zhang, H. P., Zhang, L., Luo, J., Zhang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep20913 · Cited by 229
Circulating tumor cells: clinical validity and utility
Cabel, L., Proudhon, C., Gortais, H., Loirat, D., Coussy, F., Pierga, J., & Bidard, F. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1105-2 · Cited by 223
Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model
Zhang, Z., Shiratsuchi, H., Lin, J., Chen, G., Reddy, R. M., Azizi, E., Fouladdel, S., Chang, A. C., Lin, L., Jiang, H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2592 · Cited by 207
Clinical utility of circulating tumor cells: an update
Vasseur, A., Kiavué, N., Bidard, F., Pierga, J., & Cabel, L. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12869 · Cited by 204
Advanced liquid biopsy technologies for circulating biomarker detection
Soda, N., Rehm, B. H. A., Sonar, P. M., Nguyen, N., & Shiddiky, M. J. A. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01490j · Cited by 205
Technologies for label-free separation of circulating tumor cells: from historical foundations to recent developments
Jin, C., McFaul, S. M., Duffy, S. P., Deng, X., Tavassoli, P., Black, P. C., & Ma, H. (2013) · Lab on a Chip · doi:10.1039/c3lc50625h · Cited by 196
Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
Spoerke, J. M., O'Brien, C. L., Huw, L. Y., Koeppen, H., Fridlyand, J., Brachmann, R. K., Haverty, P. M., Pandita, A., Mohan, S., Sampath, D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2347 · Cited by 181
Self-citation
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
Saura, C., Roda, D., Roselló, S., Oliveira, M., Macarulla, T. M., Fidalgo, J. A. P., Morales‐Barrera, R., Sanchis, J. M., Musib, L. C., Budha, N. R., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0512 · Cited by 173
Ultrahigh-throughput magnetic sorting of large blood volumes for epitope-agnostic isolation of circulating tumor cells
Mishra, A., Dubash, T. D., Jon, F., Jewett, M. K., Garre, S., Karabacak, M., Rabe, D. C., Mutlu, B. R., Walsh, J. R., Kapur, R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006388117 · Cited by 172
Enrichment, detection and clinical significance of circulating tumor cells
Arya, S. K., Lim, B., & Rahman, A. R. A. (2013) · Lab on a Chip · doi:10.1039/c3lc00009e · Cited by 168
Enrichment and single-cell analysis of circulating tumor cells
Song, Y., Tian, T., Shi, Y., Liu, W., Zou, Y. W., Khajvand, T., Wang, S., Zhu, Z., & Yang, C. J. (2016) · Chemical Science · doi:10.1039/c6sc04671a · Cited by 170
Self-citation
Molecular histology of lung cancer: From targets to treatments
Wood, S. L., Pernemalm, M., Crosbie, P. A. J., & Whetton, A. D. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.02.008 · Cited by 163
Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?
Ignatiadis, M., & Dawson, S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu480 · Cited by 161
Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer
Tjensvoll, K., Lapin, M., Buhl, T., Oltedal, S., Berry, K. S.-O., Gilje, B., Søreide, J. A., Javle, M. M., Nordgård, O., & Smaaland, R. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.11.012 · Cited by 157
Current approaches for avoiding the limitations of circulating tumor cells detection methods—implications for diagnosis and treatment of patients with solid tumors
Kowalik, A., Kowalewska, M., & Góźdź, S. S. (2017) · Translational research · doi:10.1016/j.trsl.2017.04.002 · Cited by 156
Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment
Marchetti, A., Grammastro, M. D., Felicioni, L., Malatesta, S., Filice, G., Centi, I., Pas, T. M. D., Santoro, A., Chella, A., Brandes, A. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103883 · Cited by 152
Three-color crystal digital PCR
Madic, J., Zocevic, A., Senlis, V., Fradet, E., Andre, B., Muller, S., Dangla, R., & Droniou, M. (2016) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2016.10.002 · Cited by 150
Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset
Agnoletto, C., Corrà, F., Minotti, L., Baldassari, F., Crudele, F., Cook, W. J. J., Leva, G. D., D’Adamo, P., Gasparini, P., & Volinia, S. (2019) · Cancers · doi:10.3390/cancers11040483 · Cited by 148
Liquid Biopsies, Novel Approaches and Future Directions
Armakolas, A., Kotsari, M., & Koskinas, J. S. (2023) · Cancers · doi:10.3390/cancers15051579 · Cited by 141
PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer
Wang, Y., Kim, T. H., Fouladdel, S., Zhang, Z., Soni, P., Qin, A., Zhao, L., Azizi, E., Lawrence, T. S., Ramnath, N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36096-7 · Cited by 145
A Radial Flow Microfluidic Device for Ultra‐High‐Throughput Affinity‐Based Isolation of Circulating Tumor Cells
Murlidhar, V., Zeinali, M., Grabauskiene, S., Ghannad‐Rezaie, M., Wicha, M. S., Simeone, D. M., Ramnath, N., Reddy, R. M., & Nagrath, S. (2014) · Small · doi:10.1002/smll.201400719 · Cited by 140
Circulating tumor cells as promising novel biomarkers in solid cancers
Lianidou, E. S., Strati, A. D., & Markou, A. N. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.896316 · Cited by 138
Liquid biopsy for lung cancer early detection
Santarpía, M., Liguori, A., D’Aveni, A., Karachaliou, N., González‐Cao, M., Daffinà, M. G., Lazzari, C., Altavilla, G., & Rosell, R. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.81 · Cited by 134
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Gray, J. E., Okamoto, I., Sriuranpong, V., Vansteenkiste, J., Imamura, F., Lee, J. S., Pang, Y., Cobo, M., Kasahara, K., Cheng, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1126 · Cited by 130
Prognostic Significance of Circulating Tumor Cells in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis
Huang, J., Wang, K., Xu, J., Huang, J., & Zhang, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078070 · Cited by 123
Microfluidic enrichment for the single cell analysis of circulating tumor cells
Yeo, T., Tan, S. J., Lim, C. L., Lau, D. P. X., Chua, Y. W., Krisna, S. S., Iyer, G., Tan, G. S., Lim, T. K. H., Tan, D. S. W., et al. (2016) · Scientific Reports · doi:10.1038/srep22076 · Cited by 123
Multivalent Aptamer Functionalized Ag2S Nanodots/Hybrid Cell Membrane‐Coated Magnetic Nanobioprobe for the Ultrasensitive Isolation and Detection of Circulating Tumor Cells
Ding, C., Zhang, C., Cheng, S., & Xian, Y. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909781 · Cited by 121
Lung Cancer Biomarkers
Hoseok, I., & Cho, J. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.07.003 · Cited by 121
Going with the Flow: From Circulating Tumor Cells to DNA
Bidard, F., Weigelt, B., & Reis-Filho, J. S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006305 · Cited by 123
Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens
Malekzadeh, P., Yossef, R., Cafri, G., Paria, B. C., Lowery, F. J., Jafferji, M. S., Good, M. L., Sachs, A., Copeland, A. R., Kim, S. P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1874 · Cited by 118
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
Tamminga, M., de Wit, S., Hiltermann, T. J. N., Timens, W., Schuuring, E. M. D., Terstappen, L. W. M. M., & Groen, H. J. M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0649-2 · Cited by 120
The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC
Nygaard, A. D., Holdgaard, P. C., Spindler, K.-L. G., Pallisgaard, N., & Jakobsen, A. K. M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.705 · Cited by 115
Circulating Tumor DNA Outperforms Circulating Tumor Cells for KRAS Mutation Detection in Thoracic Malignancies
Freidin, M. B., Freydin, M., Leung, M., Montero, Á., Nicholson, A. G., & Lim, E. K. S. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.242453 · Cited by 110
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
Yanagita, M., Redig, A. J., Paweletz, C. P., Dahlberg, S. E., O’Connell, A., Feeney, N. B., Taibi, M., Boucher, D. H., Oxnard, G. R., Johnson, B. E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0909 · Cited by 109
The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer
Kapeleris, J., Kulasinghe, A., Warkiani, M. E., Vela, I., Kenny, L., O'Byrne, K. J., & Punyadeera, C. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00311 · Cited by 111
Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment
Muinelo‐Romay, L., Vieito, M., Abalo, A., Alonso‐Nocelo, M., Barón, F., Anido, U., Brozos-Vázquez, E., Vázquez, F., Aguín, S., Abal, M., et al. (2014) · Cancers · doi:10.3390/cancers6010153 · Cited by 107
Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring
Pérez-Callejo, D., Romero, A., Provencio, M., & Torrente, M. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.10.07 · Cited by 111
Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer
Malý, V., Malý, O., Kološtová, K., & Bobek, V. (2019) · In Vivo · doi:10.21873/invivo.11571 · Cited by 104
EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
Ke, E., & Wu, Y.-L. L. C. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.09.003 · Cited by 101
Aptamers Selected to Postoperative Lung Adenocarcinoma Detect Circulating Tumor Cells in Human Blood
Сергеевна, З. Г., Kolovskaya, O. S., Zamay, T. N., Glazyrin, Y. E., Krat, A. V., Zubkova, O. A., Spivak, E. A., Wehbe, M., Gargaun, A., Muharemagic, D., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.108 · Cited by 98
Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?
Fariñas, S. C., Lewintre, E. J., Herreros‐Pomares, A., & Camps, C. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.10.02 · Cited by 97
Liquid biomarkers in melanoma: detection and discovery
Lim, S. Y., Lee, J., Diefenbach, R. J., Kefford, R. F., & Rizos, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0757-5 · Cited by 99
Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)
Lim, M., Kim, C., Sunkara, V., Kim, M., & Cho, Y. (2018) · Micromachines · doi:10.3390/mi9030100 · Cited by 97
EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer
Lindsay, C. R., Blackhall, F. H., Carmel, A., Fernández‐Gutiérrez, F., Gazzaniga, P., Groen, H. J. M., Hiltermann, T. J. N., Krebs, M., Loges, S., López‐López, R., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.019 · Cited by 95
A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
Wang, W., Song, Z., & Zhang, Y. (2016) · Cancer Medicine · doi:10.1002/cam4.978 · Cited by 94
Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer
Tang, Y., Qiao, G., Xu, E., Xuan, Y., Liao, M., & Yin, G. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s142149 · Cited by 97
Size-Based Differentiation of Cancer and Normal Cells by a Particle Size Analyzer Assisted by a Cell-Recognition PC Software
Shashni, B., Ariyasu, S., Takeda, R., Suzuki, T., Shiina, S., Akimoto, K., Maeda, T., Aikawa, N., Abe, R., Osaki, T., et al. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00776 · Cited by 93
The Role of CTCs as Tumor Biomarkers
Lianidou, E. S., Markou, A. N., & Strati, A. D. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7215-0_21 · Cited by 94
Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer
Ai, B., Liu, H., Huang, Y., & Peng, P. (2016) · Oncotarget · doi:10.18632/oncotarget.10069 · Cited by 92
Molecular Biomarkers of Cancer Stem/Progenitor Cells Associated with Progression, Metastases, and Treatment Resistance of Aggressive Cancers
Mimeault, M., & Batra, S. K. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0785 · Cited by 93
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups
Lindsay, C. R., Faugeroux, V., Michiels, S., Pailler, E., Facchinetti, F., Ou, D., Bluthgen, M. V., Pannet, C., Ngo‐Camus, M., Bescher, G., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx156 · Cited by 92
Current status of research and treatment for non-small cell lung cancer in never-smoking females
Saito, S., Espinoza-Mercado, F., Liu, H., Sata, N., Cui, X., & Soukiasian, H. J. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1323580 · Cited by 89
Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq
Bratman, S. V., Newman, A. M., Alizadeh, A. A., & Diehn, M. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1019476 · Cited by 88
Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
Sun, W., Yuan, X., Tian, Y., Wu, H. K., Xu, H., Hu, G., & Wu, K. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0193-6 · Cited by 86
Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non‐small‐cell lung cancer
Zhang, Z., Xiao, Y., Zhao, J., Chen, M., Xu, Y., Zhong, W., Xing, J., & Wang, M. (2015) · Respirology · doi:10.1111/resp.12696 · Cited by 85
The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring
Bracht, J. W. P., Mayo‐de‐las‐Casas, C., Berenguer, J., Karachaliou, N., & Rosell, R. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0720-z · Cited by 86
Applications of DNA-Based Liquid Biopsy for Central Nervous System Neoplasms
Wang, J., & Bettegowda, C. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.08.007 · Cited by 87
Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients
Vallée, A., Marcq, M., Bizieux, A., Kouri, C. E., Lacroix, H., Bennouna, J., Douillard, J., & Denis, M. G. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.014 · Cited by 85
Role of circulating-tumor DNA analysis in non-small cell lung cancer
Jiang, T., Ren, S., & Zhou, C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.09.013 · Cited by 84
Cell-free nucleic acid patterns in disease prediction and monitoring—hype or hope?
Crigna, A. T., Samec, M., Koklesová, L., Líšková, A., Giordano, F. A., Kubatka, P., & Golubnitschaja, O. (2020) · The EPMA Journal · doi:10.1007/s13167-020-00226-x · Cited by 80
Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System
Truini, A., Alama, A., Bello, M. G. D., Coco, S., Vanni, I., Rijavec, E., Genova, C., Barletta, G., Biello, F., & Grossi, F. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00242 · Cited by 80
Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer
Yang, X., Zhuo, M., Ye, X., Bai, H., Wang, Z., Sun, Y., Zhao, J., An, T., Duan, J., Wu, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8021 · Cited by 82
Circulating Tumor Cells as Predictive and Prognostic Biomarkers in Solid Tumors
Capuozzo, M., Ferrara, F., Santorsola, M., Zovi, A., & Ottaiano, A. (2023) · Cells · doi:10.3390/cells12222590 · Cited by 74
Liquid biopsy into the clinics: Current evidence and future perspectives
Boukovala, M. A., Westphalen, C. B., & Probst, V. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100146 · Cited by 77
Plasticity of tumor cell invasion: governance by growth factors and cytokines
Odenthal, J., Takes, R. P., & Friedl, P. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw098 · Cited by 78
Blood-based tumor biomarkers in lung cancer for detection and treatment
Mamdani, H. M., Ahmed, S. S., Armstrong, S. A., Mok, T. S. K., & Jalal, S. I. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.09.03 · Cited by 75
Clinical indications for, and the future of, circulating tumor cells
Moon, D. H., Lindsay, D. P., Hong, S., & Wang, A. Z. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.002 · Cited by 73
Quantification of Rare Circulating Tumor Cells in Non-Small Cell Lung Cancer by Ligand-Targeted PCR
Lou, J., Ben, S., Yang, G., Liang, X., Wang, X., Ni, S., & Han, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080458 · Cited by 71
Radiomics and liquid biopsy in oncology: the holons of systems medicine
Neri, E., Re, M. D., Paiar, F., Erba, P. A., Cocuzza, P., Regge, D., & Danesi, R. (2018) · Insights into Imaging · doi:10.1007/s13244-018-0657-7 · Cited by 72
Role of circulating tumor cells in future diagnosis and therapy of cancer
Potdar, P. D., & Lotey, N. (2015) · Journal of Cancer Metastasis and Treatment · doi:10.4103/2394-4722.158803 · Cited by 72
Circulating Tumor Cells in Lung Cancer
Young, R., Pailler, E., Billiot, F., Drusch, F., Barthelemy, A., Oulhen, M., Besse, B., Soria, J., Farace, F., & Vielh, P. R. (2012) · Acta Cytologica · doi:10.1159/000345182 · Cited by 72
Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors
Coakley, M. F., García-Murillas, I., & Turner, N. C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0152 · Cited by 69

Authors: Punnoose, E. A., Atwal, S., Liu, W., Raja, R., Fine, B. M., Hughes, B. G. M., Hicks, R. J., Hampton, G. M., Amler, L. C., Pirzkall, A., & Lackner, M. R.
Affiliations: Genentech (US)
ORCID: Punnoose, Elizabeth A.
Liu, Weiqun
Raja, Rajiv
Fine, Bernard M.
Hughes, Brett G.M.
Hicks, Rodney J.
Lackner, Mark R.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2012-04-15
Volume: 18
Issue: 8
Pages: 2391-2401
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-11-3148
OpenAlex: W2103077070
Cited by: 415
References: 29
Citations by year: 2026: 2 · 2025: 6 · 2024: 14 · 2023: 26 · 2022: 17 · 2021: 27 · 2020: 33 · 2019: 39 · 2018: 34 · 2017: 56 · 2016: 53 · 2015: 38 · 2014: 38 · 2013: 23 · 2012: 8
FWCI: 11.36
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: circulating tumor cells, circulating tumor DNA, non-small cell lung cancer, pertuzumab, erlotinib, EGFR expression, oncogenic mutations, predictive biomarkers, treatment response monitoring, CellSearch, FDG-PET, RECIST, progression-free survival, liquid biopsy
MeSH terms: Erlotinib Hydrochloride, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, DNA, Neoplasm, Female, Genotype, Humans, Lung Neoplasms, Male, Mutation, Neoplastic Cells, Circulating, Quinazolines, Biomarkers, Tumor, Disease-Free Survival, Endpoint Determination, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks